LGK974 No Further a Mystery
A stage I examine in Japanese patients with R/R NHL, which include ATLL people, showed a manageable basic safety profile, and 40 mg two times every week was selected for subsequent medical enhancement.The goal of the current phase IIb research was to evaluate the efficacy and security of tucidinostat in patients with R/R ATLL. This is the very fi